1. Market Research
  2. > Bacteremia - Pipeline Review, H2 2013

Bacteremia - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 59 pages

Bacteremia - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Bacteremia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bacteremia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacteremia. Bacteremia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bacteremia.
- A review of the Bacteremia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bacteremia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bacteremia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bacteremia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Bacteremia - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bacteremia Overview 6
Therapeutics Development 7
Pipeline Products for Bacteremia - Overview 7
Pipeline Products for Bacteremia - Comparative Analysis 8
Bacteremia - Therapeutics under Development by Companies 9
Bacteremia - Therapeutics under Investigation by Universities/Institutes 10
Bacteremia - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Bacteremia - Products under Development by Companies 14
Bacteremia - Products under Investigation by Universities/Institutes 15
Bacteremia - Companies Involved in Therapeutics Development 16
Cubist Pharmaceuticals, Inc. 16
Nabriva Therapeutics AG 17
Cellceutix Corporation 18
Bacteremia - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Assessment by Therapeutic Class 28
Drug Profiles 31
tedizolid phosphate - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
SIILPCV-10 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
BC-3781 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
A3-APO - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
brilacidin - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Bacteremia - Recent Pipeline Updates 39
Bacteremia - Dormant Projects 51
Bacteremia - Product Development Milestones 52
Featured News and Press Releases 52
Sep 13, 2013: Nabriva Therapeutics Presented Data on Potency, Safety, Tolerability and Pharmacokinetics of Pleuromutilin Antibiotic BC-3781 52
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate Cubicin At ICAAC 2012 53
Apr 11, 2011: Trius Announces Patent Term Extension For Torezolid Phosphate 54
Apr 04, 2011: Cubist Pharma Settles CUBICIN Patent Litigation With Teva 54
Dec 01, 2010: Cubist Receives FDA Approval For Two-Minute IV Injection Of CUBICIN 55
Jul 13, 2010: Cubist Announces Objectives Met in Phase 2 Safety Study of CUBICIN in Prosthetic Joint Infections 55
May 12, 2010: Markman Hearing in CUBICIN Patent Litigation Rescheduled to June 9, 2010 56
Dec 11, 2009: Trial Date Set for CUBICIN Patent Litigation 56
Jan 05, 2009: Cubist Pharmaceuticals, the Developer of CUBICIN, Announces Submission of 2 INDs Targeting Serious Infections Caused by MDR Gram-negative Pathogens and by Clostridium difficile 56
Oct 21, 2008: CUBICIN Outcomes Registry and Experience (CORE) Marks Milestone 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59



List of Tables

Number of Products under Development for Bacteremia, H2 2013 7
Number of Products under Development for Bacteremia - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Comparative Analysis by Unknown Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 15
Bacteremia - Pipeline by Cubist Pharmaceuticals, Inc., H2 2013 16
Bacteremia - Pipeline by Nabriva Therapeutics AG, H2 2013 17
Bacteremia - Pipeline by Cellceutix Corporation, H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Stage and Target, H2 2013 21
Number of Products by Stage and Mechanism of Action, H2 2013 23
Number of Products by Stage and Route of Administration, H2 2013 25
Number of Products by Stage and Molecule Type, H2 2013 27
Number of Products by Stage and Therapeutic Class, H2 2013 30
Bacteremia Therapeutics - Recent Pipeline Updates, H2 2013 39
Bacteremia - Dormant Projects, H2 2013 51



List of Figures

Number of Products under Development for Bacteremia, H2 2013 7
Number of Products under Development for Bacteremia - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Top 10 Target, H2 2013 20
Number of Products by Stage and Top 10 Target, H2 2013 21
Number of Products by Top 10 Mechanism of Action, H2 2013 22
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 23
Number of Products by Top 10 Route of Administration, H2 2013 24
Number of Products by Stage and Top 10 Route of Administration, H2 2013 25
Number of Products by Top 10 Molecule Type, H2 2013 26
Number of Products by Stage and Top 10 Molecule Type, H2 2013 27
Number of Products by Top 10 Therapeutic Class, H2 2013 28
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 29



Companies Mentioned

Cubist Pharmaceuticals, Inc.
Nabriva Therapeutics AG
Cellceutix Corporation

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.